ClinicalTrials.Veeva

Menu

Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors (PelBurd)

T

Toulouse University Hospital

Status

Enrolling

Conditions

Alopecia Areata

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05588310
RC31/22/0054
2022-A00986-37 (Other Identifier)

Details and patient eligibility

About

Alopecia areata (AA) is a complex autoimmune disorder with an estimated lifetime risk of 1.7% where both genetic pre-disposition and environmental factors contribute. It typically presents with sharply demarcated round patches of non-scarring hair loss that may present at any age. Many patients with AA are dissatisfied with current medical treatments and use alternative therapies and cosmetics. This study will generate new data on the current situation of psychosocial and financial burden of AA. It will help to identify unmet needs and to understand the disease issues. It will also be the basis for the planification of future supporting measures.

Full description

Alopecia areata (AA) is a complex autoimmune disorder with an estimated lifetime risk of 1.7% where both genetic pre-disposition and environmental factors contribute. It typically presents with sharply demarcated round patches of non-scarring hair loss that may present at any age. Current medical therapies (topical or systemic) for AA are not reliably effective, particularly for severe disease and there is no robust evidence from high-quality randomized controlled trials. Patients with AA experience significant mental health and health related quality of life (HRQoL) impairment. Furthermore, at the country level, skin conditions such as AA ranged from 2nd to 11th leading cause of years lived with disability. It was shown that AA appears to affect all countries across the world similarly, and the health burden has remained stable despite substantial advances in healthcare and health-related resources. More recently, Mesinkovska et al demonstrated that the impact of AA extends beyond cosmetic concerns and carries a considerable psychosocial burden.

Many patients with AA are dissatisfied with current medical treatments and use alternative therapies and cosmetics. Cosmetics and not reimbursed treatments can weigh heavily on patients spending.This study will generate new data on the current situation of psychosocial and financial burden of AA. It will help to identify unmet needs and to understand the disease issues. It will also be the basis for the planification of future supporting measures.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (> 18 years).
  • Alopecia Areata whose diagnosis has been confirmed by a dermatologist according to the standardized diagnostic criteria.
  • < 2 years duration of current episode of scalp hair loss.
  • Severity > S2 (> 25% hair loss) as assessed by the Alopecia Tool (SALT).

Exclusion criteria

  • Patients under juridical protection.
  • Patients not covered by social security.
  • Patients unable to understand French

Trial contacts and locations

1

Loading...

Central trial contact

Juliette Mazereeuw-Hautier, Pr; Hélène TEXIER

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems